JP2008542214A5 - - Google Patents

Download PDF

Info

Publication number
JP2008542214A5
JP2008542214A5 JP2008512730A JP2008512730A JP2008542214A5 JP 2008542214 A5 JP2008542214 A5 JP 2008542214A5 JP 2008512730 A JP2008512730 A JP 2008512730A JP 2008512730 A JP2008512730 A JP 2008512730A JP 2008542214 A5 JP2008542214 A5 JP 2008542214A5
Authority
JP
Japan
Prior art keywords
compound
formula
cancer
combination according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008512730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008542214A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/004524 external-priority patent/WO2006125540A1/en
Publication of JP2008542214A publication Critical patent/JP2008542214A/ja
Publication of JP2008542214A5 publication Critical patent/JP2008542214A5/ja
Pending legal-status Critical Current

Links

JP2008512730A 2005-05-27 2006-05-13 疾患を処置するためのジアリールウレア化合物およびｐｉ３、ａｋｔキナーゼまたはｍｔｏｒ阻害剤（ラパマイシン）を含む組合せ治療 Pending JP2008542214A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05011477 2005-05-27
PCT/EP2006/004524 WO2006125540A1 (en) 2005-05-27 2006-05-13 Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment

Publications (2)

Publication Number Publication Date
JP2008542214A JP2008542214A (ja) 2008-11-27
JP2008542214A5 true JP2008542214A5 (https=) 2009-05-07

Family

ID=36636325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008512730A Pending JP2008542214A (ja) 2005-05-27 2006-05-13 疾患を処置するためのジアリールウレア化合物およびｐｉ３、ａｋｔキナーゼまたはｍｔｏｒ阻害剤（ラパマイシン）を含む組合せ治療

Country Status (11)

Country Link
EP (1) EP1888067A1 (https=)
JP (1) JP2008542214A (https=)
KR (1) KR20080018908A (https=)
CN (1) CN101257903A (https=)
AU (1) AU2006251429A1 (https=)
BR (1) BRPI0610048A2 (https=)
CA (1) CA2609389A1 (https=)
IL (1) IL187508A0 (https=)
MX (1) MX2007014726A (https=)
RU (1) RU2007148266A (https=)
WO (1) WO2006125540A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
ATE482693T1 (de) 2005-03-07 2010-10-15 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
US20100129321A1 (en) * 2005-12-15 2010-05-27 Bayer Healthcare Llc Diaryl urea for treating virus infections
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2675980C (en) 2007-01-19 2016-06-21 Bayer Healthcare Llc Use of dast for treatment of cancers with acquired resistance to kit inhibitors
JP2010516692A (ja) * 2007-01-19 2010-05-20 バイエル・ヘルスケア・エルエルシー 化学療法剤に対し抵抗性を有する癌の処置
US7947723B2 (en) 2008-02-01 2011-05-24 Spelman College Synthesis and anti-proliferative effect of benzimidazole derivatives
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
JP2011525503A (ja) * 2008-06-25 2011-09-22 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全を処置するためのジアリールウレア
WO2010038165A1 (en) * 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
CA2763589A1 (en) * 2009-05-28 2010-12-02 President And Fellows Of Harvard College N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
CN102775385A (zh) * 2011-05-10 2012-11-14 湖南有色凯铂生物药业有限公司 N-取代苯基-n’-取代杂环脲类化合物及其作为抗癌药物的应用
CN102643229A (zh) * 2012-01-17 2012-08-22 湖南有色凯铂生物药业有限公司 N-((4-氯-3-三氟甲基)苯基)-n’-((2-氟-4-(2-氨基甲酰基)-4-吡啶基氧)苯基)脲及其作为抗癌药物的应用
CN102885814A (zh) * 2012-01-17 2013-01-23 湖南有色凯铂生物药业有限公司 一种化合物及其作为抗癌药物的应用
CN102940884B (zh) * 2012-11-19 2013-11-06 上海市肿瘤研究所 一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用
WO2014145386A2 (en) 2013-03-15 2014-09-18 University Of Florida Research Foundation Incorporated Novel allosteric inhibitors of thymidylate synthase
ES2881214T3 (es) * 2014-12-17 2021-11-29 Pfizer Formulaciones de un inhibidor de PI3K/mTOR para la administración intravenosa
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
WO2016209688A1 (en) 2015-06-24 2016-12-29 University Of Florida Research Foundation, Incorporated Compositions for the treatment of cancer and uses thereof
CN104906086A (zh) * 2015-06-24 2015-09-16 安徽四正医药科技有限公司 吲哚-3-甲醇、二吲哚甲烷及其衍生物用于治疗肾小球肾炎药物的应用
KR102544163B1 (ko) * 2022-08-10 2023-06-16 주식회사 하이밸 소음저감형 유량 및 압력 조절용 감압밸브
CN115804844B (zh) * 2022-09-26 2024-05-10 郑州大学 靶向抑制pak4的抑制剂在制备肿瘤防治药剂中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663978B1 (en) * 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Similar Documents

Publication Publication Date Title
JP2008542214A5 (https=)
RU2007148266A (ru) Комбинированная терапия с использованием соединения диарилмочевины и ингибиторов pi3, akt-киназы или mtor (рапамицины) для лечения рака
JP2008545670A5 (https=)
Finn Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition
EP2370076B1 (en) Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor
EP2349275B1 (en) Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor.
NZ602266A (en) Macrocycles as factor xia inhibitors
RU2016101364A (ru) СПОСОБ ПРЕДСКАЗАНИЯ ТЕРАПЕВТИЧЕСКОЙ ЭФФЕКТИВНОСТИ ИНГИБИТОРА P13K/AKT/mTOR НА ОСНОВАНИИ ЭКСПРЕССИИ PHLDA1 ИЛИ PIK3C2B
JP2015532642A5 (https=)
JP2011001339A5 (https=)
WO2012156756A3 (en) Macrocyclic compounds as protein kinase inhibitors
WO2011113802A3 (en) Imidazopyridine and purine compounds, compositions and methods of use
WO2012048058A3 (en) Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
JP2004525950A (ja) ラパマイシンとゲムシタビンまたはフルオロウラシルなどの、抗腫瘍剤の組み合わせ
WO2010145197A8 (en) Novel 6-arylamino pyridone sulfonamides and 6-arylamino pyrazinone sulfonamdies as mek inhibitors
AU2012358219A1 (en) Methods and compositions for combination therapy using P13K/mTOR inhibitors
JP2003510329A5 (https=)
IL292659A (en) Methods for treating breast cancer ar plus
ZA200508029B (en) Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor
JP2021522211A5 (https=)
WO2012075253A3 (en) Pharmaceutical compositions
MX2014009640A (es) Metodos de tratamientos de fibrosis.
RU2016138795A (ru) Композиции на основе циклодекстрина и производного будесонида и способы их получения
JP2016510796A5 (https=)
RU2016104437A (ru) Соединения хинина, способ их получения и их медицинское применение